Daiichi Sankyo (TYO: 46568) has launched Enhertu (fam-trastuzumab deruxtecan-nxki), an HER2 directed antibody-drug conjugate (ADC), in the USA.
The launch of the product comes a few weeks after US approval was granted, many months earlier than the scheduled action date. The US Food and Drug Administration had been expected to provide a verdict in the second quarter of 2020.
The early launch will accelerate availability for a drug which is predicted to reach peak annual sales of more than $5 billion. Initial approval is in the advanced or refractory breast cancer setting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze